Abstract library

975 results for "multimodality treatment".
#107 Results of the Gastroenteropancreatic NETs Spanish Registry in the 2001-2010 period
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEPNETs) are infrequent and heterogeneous neoplasms that have conditioned the lack of verified epidemiologic data.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Jaume Capdevila
#552 Outcomes After Liver Resection and Multidisciplinary Management of Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases
Introduction: Metastatic liver disease from neuroendocrine tumors (mNETs) has a significant impact on prognosis. Although complete surgical resection remains the only potentially curative therapy, a multimodal approach is becoming the standard by which it is managed.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Douglas Quan
Authors: Fehr A, Bhatia P, Kocha W, Reid R, ...
#1456 Retreatment with Peptide-Receptor Radionuclide Therapy: Effects on Long-term Survival, Renal and Bone Marrow Toxicity Using Yttrium-90 vs. Lutetium-177
Introduction: PRRT is an effective treatment for metastatic NETs. The effect of PRRT retreatment is unknown.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Joseph Machta
Keywords: PRRT, retreatment
#2161 Outcomes of Locoregional Treatment for Unifocal Progression in Widespread Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: New systemic treatments have improved the therapeutic landscape for patients with progressive, metastatic GEP-NETs. While drugs such as everolimus are appropriate for patients with widespread disease progression, local treatment approaches may be more appropriate for patients with unifocal progression.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Taymeyah Al-Toubah
Authors: Al-Toubah T, Cives M, Anaya D, Soares H, ...
#393 Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Differential Response of Bone Versus Soft Tissue Lesions
Introduction: Little is known about the treatment response of bone lesions to treatment with [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Esther I. Van Vliet
#632 Strategy of Combining Liver-directed Local Treatment with Systemic Treatment in Patients with Liver Metastasis of Neuroendocrine Tumor
Introduction: Little is known about the clinical outcomes of liver-directed local treatment (tx) in combination with systemic tx in patients with liver metastasis of neuroendocrine tumor (NET).
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Do-Youn Oh
Authors: Kim S, Kim J, Han S, Oh D Y, ...
#1132 177Lu-Dotatate Re-Treatment in G1-G2 Gastro-Entero-Pancreatic (GEP) NETs
Introduction: PRRT is a valid and well tollerated therapy for G1-G2GEP-NETs. A median PFS of >22 mo. has been reported after PRRT and OS of > 5 years is frequent.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini
#137 Extensive ""multitasking"" surgery for advanced neuroendocrine tumors is safe and effective
Introduction: Management of advanced NETs is controversial, related to degree of intervention; the pendulum is swinging towards a more aggressive interventional approach. Our Center's philosophy is to offer a systematic, planned multimodality treatment for patients with advanced NETs.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD MICHAIL K Shafir
#268 Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas
Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: M.D. Ingrid Holst Olsen
#1171 Clinical Characteristics and Treatment Outcome of Six Advanced G3 Well-Differentiated Neuroendocrine Tumors
Introduction: According to 2010 WHO grading system, all neuroendocrine neoplasms were divided into G1/G2/G3 based on Ki-67 and mitotic count. However, differentiation was also very important for the biological behavior and treatment strategy.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Ru Jia
Authors: Jia R, Chen H E, Chen Y L, Ge F J, ...